[et_pb_section bb_built=”1″ admin_label=”section” fullwidth=”on” next_background_color=”#000000″ global_module=”322″][et_pb_fullwidth_menu global_parent=”322″ _builder_version=”3.0.106″ menu_id=”7″ submenu_direction=”downwards” fullwidth_menu=”off” background_layout=”dark” module_class=”main-navigation” \/][\/et_pb_section][et_pb_section bb_built=”1″ fullwidth=”off” specialty=”on” prev_background_color=”#000000″ next_background_color=”#1d1d1d”][et_pb_column type=”2_3″ specialty_columns=”2″][et_pb_row_inner locked=”off”][et_pb_column_inner type=”4_4″ saved_specialty_column_type=”2_3″][et_pb_post_title _builder_version=”3.0.106″ title=”on” meta=”on” author=”on” date=”on” categories=”on” comments=”on” featured_image=”on” featured_placement=”above” text_color=”dark” text_background=”off” locked=”on” parent_locked=”off” \/][et_pb_text _builder_version=”3.17.6″ background_layout=”light” parent_locked=”off”]<\/p>\n
Our\u00a0Barrier immunology<\/a>\u00a0Deputy Branch Lead\u00a0Dr Sean Knight<\/a>\u00a0has been awarded a\u00a0BMA Foundation<\/a>\u00a0J Moulton grant for research into Long COVID.<\/p>\n Up to 70 percent of patients hospitalised for COVID-19 pneumonitis have persistent symptoms several months after the acute infection. Often, no discernible organ damage is found, and patients are diagnosed with Long COVID.\u00a0New research to improve our understanding of inflammation in Long COVID could help to unlock potential future treatments.<\/p>\n Dr Knight explained:<\/p>\n \u00a0\u201cGiven the scale of immune dysregulation in acute COVID-19,\u00a0it is expected that parts of the immune system will stay activated for some time.<\/p>\n \u00a0<\/p>\n \u201cWe have previously defined the key innate and adaptive immune signatures associated with acute COVID-19 and have now collected blood samples from our patients as they recover.<\/p>\n \u00a0<\/p>\n \u201cThis funding will be used to compare the rate of recovery of COVID-19 immune signatures in patients who have made a full recovery to those developing Long COVID. Identifying the key pathways associated with Long COVID will provide insight to drive further mechanistic work, as well as identify potential therapeutic targets.<\/p>\n<\/blockquote>\n This funding continues the Lydia Becker Institute\u2019s research on\u00a0COVID-19<\/a>\u00a0and our collaborations with partners such as the Northern Care Alliance.<\/p>\n\n